{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T09:16:36Z","timestamp":1792401396178,"version":"4.4.0"},"reference-count":98,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Viral-based cancer therapies have tremendous potential, especially in the context of treating poorly infiltrated cold tumors. However, in tumors with intact anti-viral interferon (IFN) pathways, while some oncolytic viruses induce strong innate and adaptive immune responses, they are neutralized before exerting their therapeutic effect. Arenaviruses, particularly the lymphocytic choriomeningitis virus (LCMV) is a noncytopathic virus with preferential cancer tropism and evolutionary mechanisms to escape the immune system for longer and to block early clearance. These escape mechanisms include inhibition of the MAVS dependent IFN pathway and spike protein antigen masking. Regarding its potential for cancer treatment, LCMV is therefore able to elicit long-term responses within the tumor microenvironment (TME), boost anti-tumor immune responses and polarize poorly infiltrating tumors towards a hot phenotype. Other arenaviruses including the attenuated Junin virus vaccine also have anti-tumor effects. Furthermore, the LCMV and Pichinde arenaviruses are currently being used to create vector-based vaccines with attenuated but replicating virus. This review focuses on highlighting the potential of arenaviruses as anti-cancer therapies. This includes providing a molecular understanding of its tropism as well as highlighting past and present preclinical and clinical applications of noncytophatic arenavirus therapies and their potential in bridging the gap in the treatment of cancers weakly responsive or unresponsive to oncolytic viruses. In summary, arenaviruses represent promising new therapies to broaden the arsenal of anti-tumor therapies for generating an immunogenic tumor microenvironment<\/jats:p>","DOI":"10.3389\/fimmu.2023.1110522","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T04:42:44Z","timestamp":1679632964000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Arenaviruses: Old viruses present new solutions for cancer therapy"],"prefix":"10.3389","volume":"14","author":[{"given":"Pawe\u0142","family":"Stachura","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Stencel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Borkhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra A.","family":"Pandyra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00315","article-title":"Immuno-oncology: Emerging targets and combination therapies","volume":"8","author":"Marshall","year":"2018","journal-title":"Front Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2022.04.010","article-title":"Turning cold tumors hot: From molecular mechanisms to clinical applications","volume":"43","author":"Zhang","year":"2022","journal-title":"Trends Immunol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2020.02.022","article-title":"Turning cold into hot: Firing up the tumor microenvironment","volume":"6","author":"Duan","year":"2020","journal-title":"Trends Cancer."},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1172\/JCI131572","article-title":"Targeting the innate immunoreceptor RIG-I overcomes melanoma-intrinsic resistance to T cell immunotherapy","volume":"130","author":"Such","year":"2020","journal-title":"J Clin Invest"},{"key":"B5","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.3390\/cancers14194701","article-title":"Oncolytic adenoviruses: The cold war against cancer finally turns hot","volume":"14","author":"Oronsky","year":"2022","journal-title":"Cancers (Basel)."},{"key":"B6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/biomedicines6040094","article-title":"Recombinant viruses for cancer therapy","volume":"6","author":"Chulpanova","year":"2018","journal-title":"Biomedicines."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2010.09.020","article-title":"Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy","volume":"204","author":"Brun","year":"2011","journal-title":"Am J obstetrics gynecology."},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory Large b-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"New Engl J Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"New Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.coi.2018.03.008","article-title":"Oncolytic viruses and immunity","volume":"51","author":"Chaurasiya","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000180","article-title":"Adapted ECHO-7 virus rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study","volume":"25","author":"Doni\u0146a","year":"2015","journal-title":"Melanoma Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.2174\/1568009618666171129221503","article-title":"Oncorine, the world first oncolytic virus medicine and its update in China","volume":"18","author":"Liang","year":"2018","journal-title":"Curr Cancer Drug targets."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2020.01.001","article-title":"Oncolytic viruses and the immune system: The dynamic duo","volume":"17","author":"Lemos de Matos","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3236","DOI":"10.1038\/s41467-019-11137-5","article-title":"Molecular retargeting of antibodies converts immune defense against oncolytic viruses into cancer immunotherapy","volume":"10","author":"Niemann","year":"2019","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/hep.23640","article-title":"Tissue macrophages suppress viral replication and prevent severe immunopathology in an interferon-i-dependent manner in mice","volume":"52","author":"Lang","year":"2010","journal-title":"Hepatol (Baltimore Md)."},{"key":"B17","doi-asserted-by":"publisher","first-page":"14447","DOI":"10.1038\/ncomms14447","article-title":"Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression","volume":"8","author":"Kalkavan","year":"2017","journal-title":"Nat Commun"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.01751","article-title":"Review of mammarenavirus biology and replication","volume":"9","author":"Hallam","year":"2018","journal-title":"Front Microbiol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/v5010241","article-title":"Arenavirus variations due to host-specific adaptation","volume":"5","author":"Zapata","year":"2013","journal-title":"Viruses."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1126\/science.282.5396.2079","article-title":"Identification of alpha-dystroglycan as a receptor for lymphocytic choriomeningitis virus and lassa fever virus","volume":"282","author":"Cao","year":"1998","journal-title":"Science."},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/nature05539","article-title":"Transferrin receptor 1 is a cellular receptor for new world haemorrhagic fever arenaviruses","volume":"446","author":"Radoshitzky","year":"2007","journal-title":"Nature."},{"key":"B22","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.chom.2017.10.002","article-title":"NRP2 and CD63 are host factors for lujo virus cell entry","volume":"22","author":"Raaben","year":"2017","journal-title":"Cell Host Microbe"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1099\/vir.0.057000-0","article-title":"Comparative analysis of disease pathogenesis and molecular mechanisms of new world and old world arenavirus infections","volume":"95","author":"McLay","year":"2014","journal-title":"J Gen Virol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01613-17","article-title":"Axl can serve as entry factor for lassa virus depending on the functional glycosylation of dystroglycan","volume":"92","author":"Fedeli","year":"2018","journal-title":"J Virol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.12-0176","article-title":"Cell surface molecules involved in infection mediated by lymphocytic choriomeningitis virus glycoprotein","volume":"74","author":"Shimojima","year":"2012","journal-title":"J Vet Med Sci"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2119676119","article-title":"CD164 is a host factor for lymphocytic choriomeningitis virus entry","volume":"119","author":"Bakkers","year":"2022","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009996","article-title":"Heparan sulfate proteoglycans serve as alternative receptors for low affinity LCMV variants","volume":"17","author":"Volland","year":"2021","journal-title":"PLoS Pathog"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.75.1.448-457.2001","article-title":"Differences in affinity of binding of lymphocytic choriomeningitis virus strains to the cellular receptor alpha-dystroglycan correlate with viral tropism and disease kinetics","volume":"75","author":"Smelt","year":"2001","journal-title":"J Virol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s42003-021-02028-x","article-title":"Slow viral propagation during initial phase of infection leads to viral persistence in mice","volume":"4","author":"Xu","year":"2021","journal-title":"Commun Biol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0053273","article-title":"LCMV glycosylation modulates viral fitness and cell tropism","volume":"8","author":"Bonhomme","year":"2013","journal-title":"PLoS One"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.e07-04-0374","article-title":"Old world arenavirus infection interferes with the expression of functional alpha-dystroglycan in the host cell","volume":"18","author":"Rojek","year":"2007","journal-title":"Mol Biol Cell"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01331-07","article-title":"Cellular entry of lymphocytic choriomeningitis virus","volume":"82","author":"Rojek","year":"2008","journal-title":"J Virol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.82808-0","article-title":"Characterization of junin arenavirus cell entry","volume":"88","author":"Martinez","year":"2007","journal-title":"J Gen Virol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1111\/cmi.12078","article-title":"Cell entry of lassa virus induces tyrosine phosphorylation of dystroglycan","volume":"15","author":"Moraz","year":"2013","journal-title":"Cell Microbiol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01362-09","article-title":"Z proteins of new world arenaviruses bind RIG-I and interfere with type I interferon induction","volume":"84","author":"Fan","year":"2010","journal-title":"J Virol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00555-06","article-title":"Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus","volume":"80","author":"Martinez-Sobrido","year":"2006","journal-title":"J Virol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00882-07","article-title":"Differential inhibition of type I interferon induction by arenavirus nucleoproteins","volume":"81","author":"Martinez-Sobrido","year":"2007","journal-title":"J Virol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00763-17","article-title":"A map of the arenavirus nucleoprotein-host protein interactome reveals that junin virus selectively impairs the antiviral activity of double-stranded RNA-activated protein kinase (PKR)","volume":"91","author":"King","year":"2017","journal-title":"J Virol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00955-07","article-title":"Early antibodies specific for the neutralizing epitope on the receptor binding subunit of the lymphocytic choriomeningitis virus glycoprotein fail to neutralize the virus","volume":"81","author":"Eschli","year":"2007","journal-title":"J Virol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nature04444","article-title":"Restoring function in exhausted CD8 T cells during chronic viral infection","volume":"439","author":"Barber","year":"2006","journal-title":"Nature."},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: A common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.161.5.2187","article-title":"Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo","volume":"161","author":"Prevost-Blondel","year":"1998","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/1521-4141(200009)30:9<2507::AID-IMMU2507>3.0.CO;2-V","article-title":"Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen","volume":"30","author":"Prevost-Blondel","year":"2000","journal-title":"Eur J Immunol"},{"key":"B45","article-title":"Effect of the virus of lymphocytic choriomeningitis on the course of leukemia in guinea pigs and mice","volume":"17","author":"Haas","year":"1956","journal-title":"J Natl Cancer Inst"},{"key":"B46","article-title":"Observations with a variant of lymphocytic choriomeningitis virus in mouse tumors","volume":"30","author":"Eiselein","year":"1970","journal-title":"Cancer Res"},{"key":"B47","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1038\/208948a0","article-title":"Inhibition of transplantable and spontaneous murine tumours by m-p virus","volume":"208","author":"Molomut","year":"1965","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1128\/iai.7.2.309-312.1973","article-title":"Morphological and biological characteristics of the m-p strain of lymphocytic choriomeningitis virus","volume":"7","author":"Ofodile","year":"1973","journal-title":"Infect Immun"},{"key":"B49","article-title":"The effects of MP virus infection in lymphoma","volume":"31","author":"Horton","year":"1971","journal-title":"Cancer Res"},{"key":"B50","article-title":"The treatment of 18 cases of malignant disease with an arenavirus","volume":"1","author":"Webb","year":"1975","journal-title":"Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.33594\/000000472","article-title":"Arenavirus therapy in combination with checkpoint blockade as an effective way for better tumour clearance","volume":"55","author":"Bhat","year":"2021","journal-title":"Cell Physiol Biochem"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1113643108","article-title":"RNAi screening reveals requirement for host cell secretory pathway in infection by diverse families of negative-strand RNA viruses","volume":"108","author":"Panda","year":"2011","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2008","article-title":"Defects in interferon pathways as potential biomarkers of sensitivity to oncolytic viruses","volume":"28","author":"Matveeva","year":"2018","journal-title":"Rev Med Virol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-0094","article-title":"Immunosurveillance by antiangiogenesis: Tumor growth arrest by T cell-derived thrombospondin-1","volume":"74","author":"Schadler","year":"2014","journal-title":"Cancer Res"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.2.6.557","article-title":"An essential role of Th1 responses and interferon gamma in infection-mediated suppression of neoplastic growth","volume":"2","author":"Rankin","year":"2003","journal-title":"Cancer Biol Ther"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/cdd.2014.19","article-title":"IRF4 and BATF are critical for CD8\u207a T-cell function following infection with LCMV","volume":"21","author":"Grusdat","year":"2014","journal-title":"Cell Death differentiation."},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1101\/591198","article-title":"Viral infection overcomes ineffectiveness of anti-tumoral CD8+ T cell mediated cytotoxicity","author":"Zhou","year":"2019","journal-title":"bioRxiv"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01849","article-title":"Arenavirus induced CCL5 expression causes NK cell-mediated melanoma regression","volume":"11","author":"Bhat","year":"2020","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.3390\/v13081420","article-title":"Virotherapy in Germany-recent activities in virus engineering, preclinical development, and clinical studies","volume":"13","author":"Nettelbeck","year":"2021","journal-title":"Viruses"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2104","article-title":"Development of replication-defective lymphocytic choriomeningitis virus vectors for the induction of potent CD8+ T cell immunity","volume":"16","author":"Flatz","year":"2010","journal-title":"Nat Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vaccine.2016.11.063","article-title":"Development of novel replication-defective lymphocytic choriomeningitis virus vectors expressing SIV antigens","volume":"35","author":"Penaloza MacMaster","year":"2017","journal-title":"Vaccine."},{"key":"B62","doi-asserted-by":"publisher","first-page":"15327","DOI":"10.1038\/ncomms15327","article-title":"Replicating viral vector platform exploits alarmin signals for potent CD8(+) T cell-mediated tumour immunotherapy","volume":"8","author":"Kallert","year":"2017","journal-title":"Nat Commun"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1126\/science.1215418","article-title":"The alarmin interleukin-33 drives protective antiviral CD8(+) T cell responses","volume":"335","author":"Bonilla","year":"2012","journal-title":"Science."},{"key":"B64","doi-asserted-by":"publisher","first-page":"100209","DOI":"10.1016\/j.xcrm.2021.100209","article-title":"Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attack","volume":"2","author":"Bonilla","year":"2021","journal-title":"Cell Rep Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"3284","DOI":"10.1158\/1538-7445.AM2022-3284","article-title":"Abstract 3284: HB-201 and HB-202, an arenavirus-based immunotherapy, induces tumor T cell infiltration in patients with HNSCC and other HPV16+ tumors","volume":"82","author":"Edwards","year":"2022","journal-title":"Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.spen.2012.02.002","article-title":"Lymphocytic choriomeningitis virus: An underrecognized cause of neurologic disease in the fetus, child, and adult","volume":"19","author":"Bonthius","year":"2012","journal-title":"Semin Pediatr neurology."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2007.01081.x","article-title":"Prevalence of antibodies to lymphocytic choriomeningitis virus in blood donors in southeastern France","volume":"47","author":"de Lamballerie","year":"2007","journal-title":"Transfusion."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196604282741704","article-title":"Epidemic nonmeningitic lymphocytic-choriomeningitis-virus infection. an outbreak in a population of laboratory personnel","volume":"274","author":"Baum","year":"1966","journal-title":"N Engl J Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1992.03480100055030","article-title":"Lymphocytic choriomeningitis outbreak associated with nude mice in a research institute","volume":"267","author":"Dykewicz","year":"1992","journal-title":"JAMA."},{"key":"B70","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s13756-019-0524-4","article-title":"Lymphocytic choriomeningitis virus meningitis after needlestick injury: A case report","volume":"8","author":"Dr\u00e4ger","year":"2019","journal-title":"Antimicrobial resistance infection control."},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa073785","article-title":"A new arenavirus in a cluster of fatal transplant-associated diseases","volume":"358","author":"Palacios","year":"2008","journal-title":"N Engl J Med"},{"key":"B72","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/ajt.12802","article-title":"Notes from the field: A cluster of lymphocytic choriomeningitis virus infections transmitted through organ transplantation - Iowa, 2013","volume":"63","author":"Schafer","year":"2014","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198601023140104","article-title":"Lassa fever. effective therapy with ribavirin","volume":"314","author":"McCormick","year":"1986","journal-title":"N Engl J Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1503\/cmaj.051184","article-title":"Lymphocytic choriomeningitis virus","volume":"173","author":"Hoey","year":"2005","journal-title":"CMAJ."},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.3201\/eid2309.170775","article-title":"Microcephaly caused by lymphocytic choriomeningitis virus","volume":"23","author":"Delaine","year":"2017","journal-title":"Emerg Infect Dis"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1084\/jem.164.4.1075","article-title":"T Cell-mediated hepatitis in mice infected with lymphocytic choriomeningitis virus. liver cell destruction by h-2 class I-restricted virus-specific cytotoxic T cells as a physiological correlate of the 51Cr-release assay","volume":"164","author":"Zinkernagel","year":"1986","journal-title":"J Exp Med"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1408148111","article-title":"Type I interferon is a therapeutic target for virus-induced lethal vascular damage","volume":"111","author":"Baccala","year":"2014","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1159\/000149403","article-title":"Depression of pha response in patients during therapeutic infection with mp-virus","volume":"2","author":"Wilson","year":"1973","journal-title":"Intervirology."},{"key":"B79","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1200\/JCO.2021.39.15_suppl.2502","article-title":"First report of the safety\/tolerability and preliminary antitumor activity of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with HPV16+ cancers","volume":"39","author":"Ho","year":"2021","journal-title":"J Clin Oncol"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2021-LB049","article-title":"Abstract LB049: Preliminary analysis of immunogenicity of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with advanced HPV16-positive cancers","volume":"81","author":"Katchar","year":"2021","journal-title":"Cancer Res"},{"key":"B81","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1200\/JCO.2022.40.16_suppl.2517","article-title":"Recommended phase 2 dose (RP2D) of HB-200 arenavirus-based cancer immunotherapies in patients with HPV16+ cancers","volume":"40","author":"Fu","year":"2022","journal-title":"J Clin Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00856-11","article-title":"The major determinant of attenuation in mice of the Candid1 vaccine for Argentine hemorrhagic fever is located in the G2 glycoprotein transmembrane domain","volume":"85","author":"Albarino","year":"2011","journal-title":"J Virol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00397-21","article-title":"Second-generation live-attenuated Candid1 vaccine virus resists reversion and protects against lethal junin virus infection in Guinea pigs","volume":"95","author":"Gowen","year":"2021","journal-title":"J Virol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1586\/erv.12.139","article-title":"The search for animal models for lassa fever vaccine development","volume":"12","author":"Lukashevich","year":"2013","journal-title":"Expert Rev Vaccines"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.732166","article-title":"Development and characterization of a novel non-lytic cancer immunotherapy using a recombinant arenavirus vector platform","volume":"11","author":"Lauterbach","year":"2021","journal-title":"Front Oncol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0099610","article-title":"RIG-I enhanced interferon independent apoptosis upon junin virus infection","volume":"9","author":"Kolokoltsova","year":"2014","journal-title":"PLoS One"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01682-17","article-title":"Epistastic interactions within the junin virus envelope glycoprotein complex provide an evolutionary barrier to reversion in the live-attenuated Candid1 vaccine","volume":"92","author":"York","year":"2018","journal-title":"J Virol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.1890230308","article-title":"Tacaribe virus: A new alternative for Argentine hemorrhagic fever vaccine","volume":"23","author":"Carballal","year":"1987","journal-title":"J Med Virol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.000403","article-title":"The new world arenavirus tacaribe virus induces caspase-dependent apoptosis in infected cells","volume":"97","author":"Wolff","year":"2016","journal-title":"J Gen Virol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-3306","article-title":"Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency","volume":"74","author":"Muik","year":"2014","journal-title":"Cancer Res"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00709-15","article-title":"Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors","volume":"89","author":"Wollmann","year":"2015","journal-title":"J Virol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2022-0439","article-title":"Phase I study of VSV-GP (BI 1831169) as monotherapy or combined with ezabenlimab in advanced and refractory solid tumors","volume":"18","author":"Porosnicu","year":"2022","journal-title":"Future Oncol (London England)."},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/nm1670","article-title":"Extralymphatic virus sanctuaries as a consequence of potent T-cell activation","volume":"13","author":"Recher","year":"2007","journal-title":"Nat Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01848","article-title":"Neoantigen targeting-dawn of a new era in cancer immunotherapy","volume":"8","author":"Wirth","year":"2017","journal-title":"Front Immunol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","article-title":"Approaches to treat immune hot, altered and cold tumours with combination immunotherapies","volume":"18","author":"Galon","year":"2019","journal-title":"Nat Rev Drug discovery."},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.08.027","article-title":"Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy","volume":"170","author":"Ribas","year":"2017","journal-title":"Cell."},{"key":"B97","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J Clin Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1110522\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T04:42:49Z","timestamp":1679632969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1110522\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,24]]},"references-count":98,"alternative-id":["10.3389\/fimmu.2023.1110522"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1110522","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,24]]},"article-number":"1110522"}}